Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

NCT05241067 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.

NCT NCT05241067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05241067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
Lead sponsor
Pharmazz, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2027
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome (ards)